$INGR

Ingredion (INGR) insider logs new stock trades

Ingredion Inc. (INGR) SVP, Global Ops and CSCO disposed of 13,411.3751 shares of common stock at $103.46 per share on 08/31/2026, according to an SEC Form 4 filing. The transaction was part of a phantom stock plan.

Original reporting
Published Sep 1, 2026, 4:32 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 2, 2026, 3:14 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$INGR
Bearish
medium confidence
Mentioned
$INGR
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$INGRBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment, though the transaction size is modest.

02

Market read

Routine insider filing with limited trading relevance.

03

What to watch

Potential upcoming corporate actions or compensation plans not disclosed.

Relevance 4/10Novelty 4/10Timing: filed 09/01/2026

Background

Ingredion Inc. (INGR) filed a SEC Form 4 reporting insider transactions by a director/officer.

Company-level read

Ticker impact

$INGRBearishMedium confidence
Context

Form 4 shows director/officer Michael N. Levy sold 13,411.3751 shares of Ingredion at $103.46 and transferred 16.881 phantom shares on 08/31/2026.

Expected impact

Possible short‑term pressure; limited upside risk.

Evidence & confidence

The sale represents a $1.4M disposition by a senior insider, which may be interpreted as a lack of confidence, yet the amount is not material enough to drive a large move.

Market effects

Minimal impact on food ingredients sector; typical insider activity.

None

None

Counterpoint

Insider may be diversifying; sale does not necessarily signal weakness.

Key entities

  • Michael N. Levy

    SVP, Global Ops and CSCO, reported sale of common stock and phantom shares.

Related articles

$INGRMed

Ingredion (INGR), Why Is It Back In The Spotlight?

Ingredion (INGR) appointed Diego Reynoso as CFO, effective October 1, 2026. The company's share price is $104.62, with mixed recent returns. Analysts have differing views on its valuation, with AgWiz estimating it as 18.6% overvalued at a fair value of $88.23, while another DCF model values it at $222.82. The company's future performance depends on its integration of Tate & Lyle and shift to specialty ingredients.

$INGRMedAI 8/10

Ingredion's carrot fibre wins EU approval

Ingredion received EU approval for Benicaros SF Pure P, a carrot fibre, allowing its sale in the EU from July 2026. The fibre is plant-based, low-dose, and designed for use in foods, beverages, and supplements without affecting taste or texture. Ingredion acquired Benicaros in June 2026, positioning the ingredient as part of its focus on science-backed nutrition. The EU approval could boost adoption among European formulators.

$DARMedAI 8/10

A Look Back at Ingredients, Flavors & Fragrances Stocks’ Q2 Earnings: Darling Ingredients (NYSE:DAR) Vs The Rest Of The Pack

Ingredients, flavors, and fragrances stocks reported mixed Q2 earnings, with revenues missing estimates by 2.4%. Darling Ingredients (DAR) reported $1.72B revenue, up 16.4% YoY, beating estimates. Archer-Daniels-Midland (ADM) reported $22.68B revenue, up 7.2% YoY, outperforming estimates. International Flavors & Fragrances (IFF) reported $1.95B revenue, down 29.3% YoY, missing estimates. Ingredion (INGR) reported $1.85B revenue, flat YoY, topping estimates. Bunge Global (BG) reported $24.04B rev

$INGRMedAI 8/10

Ingredion (INGR) Q2 2026 Earnings Call Transcript

Ingredion (NYSE:INGR) reported Q2 2026 net sales of $1.85B (+1%) and adjusted operating income of $258M (-5%). Adjusted EPS was $2.82. Management cited Argo facility issues, Mexico currency headwinds, and rising tapioca costs. It reaffirmed 2026 adjusted EPS guidance of $10.30 to $10.90 and expects Tate & Lyle acquisition synergies of $130M run-rate by 2030.